Kura Oncology, Inc.KURA

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · kuraoncology.com

Kura Oncology is a clinical-stage biopharmaceutical company developing precision medicines for cancer, including menin inhibitors and farnesyl transferase inhibitors targeting genetically defined patient populations.

Key ratios

FCF / Sales

-152.1%TTM

2025 -104.8%2024 248.4%

Net margin

-208.5%TTM

ROA

-31.3%TTM

2025 -25.3%2024 -20.0%2023 -22.9%

ROE

-167.7%TTM

2025 -94.8%2024 -42.9%2023 -37.3%

Revenue growth

-7.3%TTM

2025 25.2%

Track KURA in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer